Home / Market News / $LQDA
benzinga Corporate Catalyst Impact 75/100 ● neutral

Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD

Oct 13, 2026, 9:52 PM UTC · Primary ticker $LQDA

Liquidia has settled a patent dispute, agreeing not to appeal a court ruling that found its YUTREPIA product infringed on a patent related to PH-ILD treatment. As a result, Liquidia will remove the PH-ILD indication from YUTREPIA's label and cease promoting it for that use, which could impact future revenue streams for the drug.

Liquidia has settled a patent infringement lawsuit concerning its YUTREPIA product's use for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company agreed not to appeal a court ruling that found it infringed on a competitor's patent and will now remove the PH-ILD indication from YUTREPIA's label. This development is negative for Liquidia as it restricts the potential market for YUTREPIA, potentially impacting future revenue and growth projections. Conversely, this could be seen as a positive for United Therapeutics (UTHR), which likely holds the '327 patent, as it reduces competition in the PH-ILD treatment space. Short-term, LQDA stock may see downward pressure due to the loss of this market segment, while UTHR might experience a slight uplift. Long-term, Liquidia will need to focus on other indications for YUTREPIA or its L606 program to offset this loss, while UTHR solidifies its market position in PH-ILD.

$LQDA negative Loss of PH-ILD indication for YUTREPIA
$UTHR positive Competitor's product loses indication, reducing competition
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.